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The long non-coding RNA landscape in juvenile
myelomonocytic leukemia
Juvenile myelomonocytic leukemia (JMML) is a rare
and aggressive myelodysplastic and myeloproliferative
disorder of early childhood. It is characterized by prolif-
eration of granulocytic and monocytic cells.1 Currently,
hematopoietic stem cell transplantation (HSCT) is the
standard of care and results in long-term overall survival
(OS) of only 50-60%.2  In approximately 90-95% of
patients, hyperactivation of the RAS/MAPK pathway can
be observed through typical mutations in NRAS and
KRAS (20-25%), PTPN11 (35%), NF1 (10-15%) or CBL
(10-15%) genes. This underlying molecular defect can in
part be used to guide patient management (e.g. no HSCT
in patients with mutations in CBL).2 Additional somatic
mutations, including mutations in SETBP1, JAK3 and
members of the polycomb repressive complex 2 (PRC2),
are associated with worse outcome.3,4 In addition, LIN28B
overexpression and DNA hypermethylation profiles can
identify JMML patients with a more aggressive clinical
course.5-7 
The non-coding transcriptome consists of a variety of
different RNA types such as tRNAs, snoRNAs,
microRNAs, circRNAs and long non-coding RNAs
(lncRNAs). LncRNAs are a class of RNA genes with a
minimum length of 200 nucleotides.8 Although only a
fraction of known lncRNAs have been functionally char-
acterized, there is growing evidence of their involvement
in  a variety of biological processes, human diseases and
malignancies.9
To explore lncRNA expression in JMML, RNA from
isolated mononuclear cell preparations from 44 previous-
ly untreated JMML patients (median age: 2.02 years) and
7 bone marrow samples from healthy controls (siblings
screened for transplantation; median age 6.83 years) was
profiled on a custom designed Agilent (8x60K) microar-
ray platform described by Volders et al.8 The dataset
(GEO Series accession n. GSE71449) had been previously
used in an mRNA expression analysis, leading to the
identification of overexpression of LIN28B in a fetal-like
subgroup of JMML patients.5 Details of patients' charac-
teristics can be found in the Online Supplementary Table
S1.
Only probes (n=23,728) representing known lncRNAs
were withheld for further analyses. Therefore, the probes
were mapped against the most up-dated version of differ-
ent lncRNA databases, including lncipedia (www.lnci-
pedia.org), Hugo Gene Nomenclature Committee
(HGNC), and Long Noncoding RNA Database v.2.0
(www.lncrnadb.org). The lncipedia 3.1 annotations for
lncRNAs have been used throughout this manuscript.
Differential gene expression analysis, with samr package
(R BioConductor) and BRB-Array tools, revealed a total
of 300 differentially expressed lncRNAs (adjusted P<0.05;
FDR<0.10) between JMML patients and controls, of
which 15 up-regulated and 285 down-regulated  in
JMML patients (Figure 1A and B and Online
Supplementary Table S2). The 5 most up-regulated
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Figure 1. Long non-coding RNA transcriptome in juvenile myelomonocytic leukemia (JMML). (A) Diagonal plot representing the average expression versus the
log2 fold change added to the average expression of lncRNAs when comparing JMML (n=44) to healthy donors (n=7). lncRNAs significantly up-regulated in
patients are represented in red and lncRNAs significantly down-regulated in blue. The names of the top 5 up- and down-regulated lncRNAs based on log2 fold
change are indicated. (B) Circos plot showing lncRNAs and mRNAs on human chromosomes. From the outside in, the first layer of the Circos plot represents a
chromosome map of the human genome. Black and white bars are chromosome cytobands, and red bars represent centromeres. The second circle  shows all
differentially expressed coding genes when comparing JMML patients with healthy donors, and the inner circle shows all differentially expressed lncRNAs. Up-
regulated lncRNA and mRNA genes are represented in red and down-regulated genes in blue. The height of the bars is representative for the fold change
between JMML and healthy donors. Names of lncRNA genes with fold change of more than  2 between JMML and healthy donors are indicated between the cir-
cles with mRNA and lncRNA genes for the down-regulated lncRNAs and in the middle of the plot for the up-regulated lncRNAs. (C) Density plots representing the
average of the normalized expression of all lncRNAs and mRNAs detected by the array in all samples (left) and in JMML samples only (right).
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lncRNAs based on log2 fold change were lnc-THADA-4,
lnc-SYF2-2, lnc-BASP1-3, lnc-ACSL1-1 and lnc-CROCC-1,
whereas lnc-SUPT3H-1, lnc-SOX6-1, lnc-HMCN1-2, lnc-
ACVR2A-2 and lnc-RAN-1 were the top 5 most down-
regulated lncRNAs. As shown in other disease entities,
the mean expression level of lncRNAs was nearly 2-fold
lower as compared to mRNA (P<0.0001) (Figure 1C). To
exclude the impact of differences in cellular composition
between JMML and healthy controls, we compared our
dataset with an lncRNA expression atlas of flow cytom-
etry sorted blood cell populations (Online Supplementary
Table S3).10 This analysis revealed 2 of 15 differentially
up-regulated lncRNAs in JMML to be specific for granu-
locytic lineage (lnc-ACSL1-1 and lnc-BASP1-3) and none
for monocytic differentiation. Conversely, one monocytic
specific lncRNA showed significant downregulation in
JMML patients (lnc-AL713998.1-2).
To explore the functional characteristics of differential-
ly expressed lncRNAs, we used a guilt-by-association
approach, based on the hypothesis that non-coding and
protein coding genes belonging to the same biological
pathways are co-ordinately regulated. Spearman’s rho
values were calculated between lncRNAs of interest and
all protein coding genes on the array. The resulting
ranked gene lists served as inputs for pre-ranked gene-set
enrichment analysis (GSEA),11 using the MSigDB.v.6.0 C2
collection and FDR<0.1. This revealed an overlap
between the 15 curated gene sets most positively corre-
lated with the top 5 up-regulated lncRNAs (Figure 2 and
Online Supplementary Table S4). Using the same approach
for the top 5 down-regulated lncRNAs, a strong overlap
both in gene sets positively correlated with these
lncRNAs, as well as negatively correlated was observed
(Figure 2 and  Online Supplementary Table S4).
Interestingly, several gene sets showed positive correla-
tion with up-regulated lncRNAs as well as negative cor-
relation with down-regulated lncRNAs, suggesting a
common pathway. Notably, these gene sets are related to
myeloid cell development, dendritic cell maturation, neu-
trophil function at skin wound, systemic lupus erythe-
matosus, and different acute myeloid leukemia (AML)
phenotypes.
Extensive cytogenetic and mutational data were avail-
able for our patient cohort and we evaluated whether the
expression of lncRNAs was associated with specific
JMML subgroups based on clinical, cytogenetic and
mutational characteristics. First, patients with elevated
fetal hemoglobin (HbF) levels for age were compared
with patients with normal HbF levels. Only 8 lncRNAs
were found differentially expressed between these two
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Figure 2. Schematic overview of the overlap between curated gene sets positively and negatively correlating with the top 5 up- and down-regulated lncRNAs.
The overlap between curated gene sets positively and negatively correlating with the top 5 up-regulated lncRNAs (lnc-THADA-4, lnc-SYF2-2, lnc-BASP1-3, lnc-
ACSL1-1 and lnc-CROCC-1) and the top 5 down-regulated lncRNAs (lnc-SUPT3H-1, lnc-SOX6-1, lnc-HMCN1-2, lnc-ACVR2A-2 and lnc-RAN-1) in juvenile
myelomonocytic leukemia (JMML) compared to healthy controls. Only gene sets with overlap in 3 or more lncRNAs are presented. The green ‘+’ symbol indicates
a positive correlation between the gene set and the lncRNA, and the red ‘-‘ symbol indicates a negative correlation between the gene set and the lncRNA. Gene
sets (anti-)correlating both with up-regulated and down-regulated lncRNAs are written in bold. Marked overlap between these gene sets can be observed sug-
gesting a common pathological pathway.
groups, all up-regulated in the group with normal HbF
levels for age (adjusted P<0.05) (Online Supplementary
Table S5). Given the strong downregulation of lnc-
C2orf54-1 and lnc-ATP6V0D2-2 in JMML patients with
elevated HbF for age (log fold change -7.4 and -2.8,
respectively), we predicted that these lncRNA would be
anti-correlated with genes involved in HbF regulation.
Indeed, HBG1 (Spearman rho value (ρ): -0.63 and -0.61),
HBBP1 (Hemoglobin Subunit Beta Pseudogene 1; ρ: -0.60
and -0.41), HBE1 (ρ: -0.37 and -0.45) and LIN28B (ρ: -
0.58 and -0.70), belonged to the top anti-correlated pro-
tein coding genes, suggesting that both lnc-C2orf54-1 and
lnc-ATP6V0D2-2 could be part of a molecular network
controlling the formation of HbF. Moreover, lnc-
ATP6V0D2-2 is associated with event-free survival (EFS)
in cytogenetically normal AML and is down-regulated in
patients with mutations in RUNX1.12 Subsequently,
patients with monosomy 7 were compared to patients
with a normal karyotype. To avoid confounding effects
due to RAS gene mutations, a 2-class analysis (mono-
somy 7 vs. normal karyotype) blocking for RAS muta-
tions through a randomized block design was applied.13
As such, different RAS mutations are considered one
group (block), eliminating variability not of interest in
this specific analysis.13 This analysis revealed a total of 36
lncRNAs significantly up-regulated in the monosomy 7
group and 5 lncRNAs down-regulated. Of note, 6 of 8
lncRNAs (lnc-C2orf54-1, PRINS, lnc-ATP6V0D2-2, lnc-
CCT8-1, lnc-SH3BGRL2-1, lnc-FRMD4A-1) down-regu-
lated in patients with elevated HbF levels for age were
significantly up-regulated in JMML patients with mono-
somy 7. This observation corresponds with the estab-
lished inverse relation between monosomy 7 and elevat-
ed HbF levels in JMML patients.2
Next, we performed pairwise analyses comparing
patients with PTPN11 (n=18), KRAS (n=11), NRAS (n=8),
NF1 (n=4) mutations or without any of the above muta-
tions (quadruple negative; n=3) to all other patients
(Online Supplementary Table S5). Patients harboring a
KRAS mutation showed 26 differentially expressed
lncRNAs (17 up-regulated and 9 down-regulated) com-
pared to JMML patients without this mutation. NF1
mutated patients were characterized by 62 down-regulat-
ed lncRNAs whereas none were significantly up-regulat-
ed. PTPN11 mutated patients were marked by differen-
tial expression of 8 lncRNAs (6 up-regulated and 2 down-
regulated) and 4 lncRNAs were differentially expressed in
NRAS mutated JMML (all up-regulated). Remarkably, in
quadruple negative patients, only one lncRNA, lnc-
ATP10A-2, was differentially up-regulated with high fold
change (FC=14.4). This lncRNA is anti-correlated with
BAP1, a key regulator of many cancer-associated path-
ways. 
Finally, we studied differentially expressed lncRNAs
between JMML patients with and without LIN28B over-
expression. Sixty-one lncRNAs were differentially
expressed of which 60 were up-regulated in JMML
patients with LIN28B overexpression (Online
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Figure 3. Stratification of juvenile myelomonocytic leukemia (JMML) patients based on lncRNA score. (A and C) Kaplan-Meier curve for overall survival (OS)
and event-free survival (EFS) after hematopoietic stem cell transplantation (HSCT) from JMML diagnosis for patients with favorable and unfavorable lncRNA
score. (B) Heatmap displaying differential gene expression (n=549 coding genes with an absolute fold change of more than 2; 238 genes up-regulated in
patients with favorable lncRNA score and 311 genes up-regulated in patients with unfavorable lncRNA score) between JMML patients with favorable and unfa-
vorable lncRNA score. Clinical annotation for “genotype” (somatic mutations in PTPN11, KRAS, NRAS and NF1; LIN28B overexpression and karyotype) and some
clinical characteristics [age group and fetal hemoglobin (HbF) level for age] are depicted on top of the heatmap. 
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Supplementary Table S5). Interestingly, both MEG3 and
MEG8 were up-regulated in LIN28B overexpression and
are known to be involved in regulation of pluripotence
and fetal development.14 
As the prognostic value of coding gene expression sig-
natures in JMML has previously been reported by
Bresolin et al.,15  we hypothesized that lncRNA expression
might influence clinical outcome. Indeed, univariable
Cox regression analysis identified 45 individual lncRNAs
highly associated with OS (P<0.001) (Online
Supplementary Table S6) of which 7 lncRNAs (UCKL1-
AS1, lnc-GPR63-5, lnc-ZSWIM2-3, lnc-RORB-1, lnc-
NPFFR2-1, lnc-EMB-3 and lnc-CCDC90A-2) remained sig-
nificantly associated with OS after multivariable Cox
regression analysis with age category (< or > 2 years old),
HbF status, karyotype  and molecular status (P<0.001).
Interestingly, these lncRNAs did not associate with
known prognostic characteristics and pre-ranked GSEA
could not identify a common (anti-)correlated gene set.
We devised an lncRNA score, derived as a linear combi-
nation of the expression of the significant lncRNAs
(method described in Garzon et al.12) and dichotomized
patients based on lncRNA score (scores below the medi-
an were classified as favorable and scores above as unfa-
vorable). Patients with unfavorable lncRNA score had a
significantly lower OS and EFS after HSCT (log rank test
P<0.001) (Figure 3A and C). Next, we compared the
expression levels of 29,654 mRNA probes (21,659 unique
genes) between patients with favorable and unfavorable
lncRNA score. We identified 549 coding genes with dif-
ferential expression between the two groups (absolute
FC ≥ 2) (Figure 3B). Together, these results suggested that
lncRNAs might be of prognostic significance in JMML.
However, studies in independent patient cohorts are 
necessary to validate the prognostic value of lncRNA
expression in JMML.
In conclusion, we documented for the first time the
lncRNA landscape in 44 JMML patients and have associ-
ated lncRNA expression with clinical and molecular char-
acteristics. We demonstrated that JMML patients exhibit
a distinct lncRNA expression profile compared to healthy
controls and different JMML subgroups have distinct
lncRNA signatures contributing to disease heterogeneity.
Follow-up studies are needed to confirm the prognostic
value of lncRNAs and to perform an integrative analysis
of lncRNA expression profiles with mutational patterns,
DNA methylation profiles and clinical patients' charac-
teristics. This study paves the way for further functional
research on the role of lncRNAs in JMML biology, and
their diagnostic and therapeutic application. 
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